Ross Stewart is part of the Translational Medicine group within MedImmune, and supports translational strategy and execution across a range of immunotherapy programs.
Prior to this he spent 7 years as part of the research group at MedImmune, which is responsible for basic biology, preclinical pharmacology and drug discovery across the oncology portfolio. During this time he helped establish preclinical platforms that support MedImmune immunotherapy programs currently in discovery and development. He led a number of preclinical programs through their discovery phase, including MEDI4736 (anti-PD-L1), played a significant role in the in-licensing of tremelimumab and was a member of the early clinical development teams for both molecules.
Prior to joining MedImmune Ross received a PhD from The University of Birmingham Medical School, where he studied the impact of CD40 signal strength in B-cell activation and survival.